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Purpose or Objective: During the course of head and neck 
radiotherapy, anatomical changes may lead to underdosage 
or hotspots in target volumes, and overdosage in organs at 
risk (OARs). The largest dose differences between planned 
and actual given OAR dose have been reported for the 
parotid glands (PGs). Dose increase to the PGs could lead to 
an increase of radiation induced side effects, justifying 
adaptive radiotherapy (ART) to reduce the PG dose. Still, ART 
procedures are labour intensive and only a fraction of 
patients will benefit. The aim of this study was to develop 
and validate a method to predict dose deviations from the 
planned PG mean dose, to select patients for adaptive 
radiotherapy (ART) up-front. 
 
Material and Methods: Planning and response (6 weeks after 
RT) CT-scans from 113 head and neck cancer patients (cohort 
A) were used to estimate deviations between planned and 
actually given PG mean dose (ΔDmean). Potential pre-
treatment selection parameters presented in recent 
literature were included in the analysis. Uni- and 
multivariable linear regression analysis for the endpoint PG 
ΔDmean was performed to select pre-treatment parameters 
eligible for patient selection. ROC curve analysis was 
performed to determine cut off values for selecting patients 
with PG ΔDmean larger than 3 Gy with a sensitivity in the 
range of 70-100%. The proposed method of patient selection 
was validated in another patient cohort consisting of 43 head 
and neck cancer patients who received weekly rescan CTs 
(cohort B). 
 
Results: In univariable analysis, pre-treatment parameters 
significantly associated with PG ΔDmean were: BMI, 
chemotherapy, T-stage, N-stage, volume of the GTV, tumour 
location, overlap of the PG with the high and low dose PTV, 
V20, V30, V40 and mean dose of the PG. In multivariable 
analysis, the initial PG mean dose remained the only 
significant parameter. ROC results were summarized in Table 
1. Selection of patients for dose deviations larger than 3 Gy 
with a sensitivity of 90% could be obtained by a threshold of 
the initial PG mean dose of 22.2 Gy (Table 1). This would 
select 62% of patients for ART in cohort A and 76% in cohort B 
with a corresponding precision of 29 and 19%, saving 38 and 
24% of patients from the labour-intensive ART procedure. 
 
Conclusion: We succeeded to develop a method to select 
patients for ART up-front by using the initial mean dose to 
the parotid gland. The labour of ART could be reduced by 24-
38% with 87-90% sensitivity, contributing to a more effective 
allocation of the department resources. 
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Background: Breast cancer radiotherapy reduces the risk of 
cancer recurrence and death. However it usually involves 
some radiation exposure of the heart which may increase the 
risk of subsequent heart disease. Epidemiological data 
suggest that the major coronary event rate increases by 7.4% 
per Gy mean heart dose1. Estimates of the absolute risks of 
radiation-related heart disease are needed to help 
oncologists plan each individual woman’s treatment. The 
absolute risk for an individual woman depends on her 
estimated cardiac radiation dose and her background risk of 
ischaemic heart disease in the absence of radiotherapy. 
When the risk is known, it can then be compared with the 
absolute benefit of the radiotherapy.  
 
Methods: Worldwide data on heart doses in breast cancer 
radiotherapy published during 2003-2013 were collated 
systematically. Analyses considered the variation in the 
typical mean heart dose according to various patient and 
treatment-related factors including laterality, target(s) 
irradiated and technique2. These heart doses were used to 
predict typical absolute cardiac risks from breast cancer 
radiotherapy using the dose-response relationship of a 7.4% 
per Gy increase in the rate of major coronary events.1 These 
risks were compared with estimates of the absolute benefits 
of breast cancer radiotherapy.  
 
Results: In left breast cancer, mean heart dose averaged 
over 398 regimens in 149 studies from 28 countries was 5.4 
Gy (range <0.1-28.6 Gy). In left-sided regimens that did not 
include the internal mammary chain, the average mean heart 
dose was 5.6 Gy (range <0.1-23.0) for inverse-planned 
intensity modulated radiation therapy, 3.4 Gy (range <0.1-
12.4) for tangential irradiation, 2.2 Gy (range <0.1-3.8) for 
brachytherapy and 0.5 Gy (range 0.1-0.8) for proton beam 
therapy. On average, inclusion of the left IMC doubled the 
heart dose. In 93 regimens where the left IMC was irradiated, 
average mean heart dose was around 8 Gy for most photon or 
electron techniques, and it varied little according to which 
other targets were irradiated. In right-sided breast cancer, 
the average mean heart dose was 3.3 Gy based on 45 
